BRIEF—Gilead adds to Sunlenca data package in HIV

US biotech major Gilead Sciences has presented data to show that twice-yearly Sunlenca (lenacapavir) has a sustained impact on health-related quality of life in people with HIV.

Sunlenca is the first long-acting injectable HIV treatment medication administered twice-yearly.

New data presented by Gilead, which reinforce the efficacy, safety, and tolerability profile of Sunlenca, include patient-reported outcomes from the Phase II/III CAPELLA trial.

The data were presented at the 12th International AIDS Society (IAS) Conference on HIV Science (IAS 2023), taking place July 23 to 26 in Brisbane, Australia.

Jared Baeten, vice president, HIV clinical development, Gilead, said: “Understanding potential real-world use of novel HIV options is essential to helping ensure they have the greatest potential impact.

“The patient-reported outcome data presented at IAS 2023 provide deep insight into the tolerability of lenacapavir, and the oral bridging data helps demonstrate how twice-yearly lenacapavir can fit into people’s lives. As we continue development of lenacapavir-based options with the goal to optimize HIV treatment, people’s experience and insights are at the center.”